Effect of Percentage of Positive Prostate Biopsy Cores on Biochemical Outcome in Low-risk PCa Treated With Brachytherapy or 3D-CRT

Urology

Volumn 73, Issue 6, 2009, Pages 1328-1334

  Pe, Mark L ^a   Trabulsi, Edouard J ^a   Kedika, Ramalinga ^a   Pequignot, Edward ^b   Dicker, Adam P ^a   Gomella, Leonard G ^a   Valicenti, Richard K ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 125; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; BIOCHEMISTRY; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; COHORT ANALYSIS; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE BIOPSY; PROSTATE CANCER; RETROSPECTIVE STUDY; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; BRACHYTHERAPY; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 67349267299     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.09.078     Document Type: Article

References (20)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Cooperberg M.R., Moul J.W., and Carroll P.R. The changing face of prostate cancer. J Clin Oncol 23 (2005) 8146-8151
3. Cooperberg M.R., Lubeck D.P., Meng M.V., et al. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 22 (2004) 2141-2149
4. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969-974
5. D'Amico A.V., Schultz D., Silver, et al. The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external beam radiation therapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 49 (2001) 679-684
6. D'Amico A.V., Whittington R., Malkowicz S.B., et al. The clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 18 (2000) 1164-1172
7. Freedland S.J., Aronson W.J., Terris M.K., et al. Percent of prostate needle biopsy cores with cancer is a significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from the SEARCH database. J Urol 169 (2003) 2136-2141
8. Rossi P.J., Clark P.E., Papagikos M.A., et al. Percentage of positive biopsies associated with freedom from biochemical recurrence after low-dose-rate prostate brachytherapy alone for clinically localized prostate cancer. Urology 67 (2006) 349-353
9. Merrick G.S., Butler W.M., Galbreath R.W., et al. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland. Int J Radiat Oncol Biol Phys 52 (2002) 664-673
10. Merrick G.S., Butler W.M., Wallner K.E., et al. Prognostic significance of percent positive biopsies in clinically organ-confined prostate cancer treated with permanent prostate brachytherapy with or without supplemental external beam radiation. Cancer J 10 (2004) 54-60
11. D'Amico A.V., Renshaw A.A., Cote C., et al. Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease. J Clin Oncol 22 (2004) 3726-3732
12. Greene F.L., Page D.L., Fleming I.D., et al., American Joint Committee on Cancer. Manual for Staging Cancer. 6th ed. (2002), Springer-Verlag, New York 337-346
13. Roach M., Hanks G., Thames H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO, Phoenix consensus conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
14. Kaplan E., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
15. Stamey T.A., McNeal J.E., Yemoto C.M., et al. Biological determinants of cancer progression in men with prostate cancer. JAMA 281 (1999) 1395-1400
16. Quinn D.I., Henshall S.M., Brenner P.C., et al. Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion. Cancer 97 (2003) 1884-1893
17. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591-1596
18. Beyer D.C., and Brachman D.G. Failure free survival following brachytherapy alone for prostate cancer: comparison with external beam radiotherapy. Radiother Oncol 57 (2000) 263-267
19. Brachman D.G., Thomas T., Hilbe J., et al. Failure-free survival following brachytherapy alone or external beam radiation alone for T1-2 prostate tumors in 2222 patients: results for a single practice. Int J Radiat Oncol Biol Phys 48 (2000) 111-117
20. Zelefsky M.J., Wallner K.E., Ling C.C., et al. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early stage prostatic cancer. J Clin Oncol 17 (1999) 517-522